Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial
    Meeting Abstract

    Richardson, P. G.; Jacobus, S. J.; Weller, E.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Postoperative morbidity after secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer: An exploratory analysis of a randomized phase II study evaluating hyperthermic intraperitoneal chemotherapy
    Meeting Abstract

    Praiss, A.; Moukarzel, L.; Chi, D.; Sonoda, Y.; Roche, K. L.; Gardner, G.; Tew, W.; Grisham, R.; O'Cearbhaill, R.; Zivanovic, O.
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Predicting outcomes in female germ cell patients using a modified International Germ Cell Cancer Collaborative Group classification system to guide management
    Meeting Abstract

    Manning-Geist, B.; Deng, L.; Knezevic, A.; Bromberg, M.; Funt, S.; Zivanovic, O.; Roche, K. L.; Sonoda, Y.; Gardner, G.; Grisham, R.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Safety and immunogenicity of anti PD-L1 (atezolizumab) given as an immune primer or concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer: An NRG oncology trial
    Meeting Abstract

    Mayadev, J.; Zamarin, D.; Deng, W.; Lankes, H.; Pesci, G.; Park, K.; Banbury, B.; Sherry, N.; Ghamande, S.; Holman, L.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas
    Journal Article

    Yoo, A.; Tang, C.; Zucker, M.; Fitzgerald, K.; DiNatale, R. G.; Rappold, P. M.; Weiss, K.; Freeman, B.; Lee, C. H.; Schultz, N.; more...
    European Urology Focus (2022)

    Fulltext@MSK | Save
  • Congenital cardiac liver cirrhosis with combined hepatocellular-cholangiocarcinoma- A case report
    Journal Article

    El Dika, I.; Shia, J.; Chen, C. L.; Paroder, V.; Carver, A.; Shamseddine, A.; Mukherji, D.; Sirohi, B.; Makondi, P. T.; Asseily, C.; more...
    Journal of Gastrointestinal Oncology (2022)

    Fulltext@MSK | Save
  • RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS
    Journal Article

    Huang, Y. J.; Chen, J. Y.; Yan, M.; Davis, A. G.; Miyauchi, S.; Chen, L.; Hao, Y.; Katz, S.; Bejar, R.; Abdel-Wahab, O.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Weirda, W. G.; Cheah, C. Y.; Roeker, L. E.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Salwender, H.; Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R.; Byrne, J.; Eliason, L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save